Esmaeili, Mohammad Hossein <br/><br/>
ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer's disease.  [electronic resource] 

 -  Brain research bulletin  03 2018 
 - 265-276 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2747 
<br/><br/><label>Standard No.: </label>10.1016/j.brainresbull.2018.01.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alzheimer Disease--drug therapy<br/>Amyloid beta-Peptides<br/>Animals<br/>Anxiety--drug therapy<br/>Corticosterone--metabolism<br/>Depression--drug therapy<br/>Disease Models, Animal<br/>Glyburide--pharmacology<br/>Hypothalamo-Hypophyseal System--drug effects<br/>KATP Channels--antagonists & inhibitors<br/>Nootropic Agents--pharmacology<br/>Peptide Fragments<br/>Pituitary-Adrenal System--drug effects<br/>Potassium Channel Blockers--pharmacology<br/>Rats, Wistar<br/>Stress, Psychological--drug therapy